Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김휘영 | * |
dc.date.accessioned | 2021-08-12T16:32:51Z | - |
dc.date.available | 2021-08-12T16:32:51Z | - |
dc.date.issued | 2021 | * |
dc.identifier.issn | 0163-2116 | * |
dc.identifier.other | OAK-29737 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/258906 | - |
dc.description.abstract | Background and Aims: The influence of direct-acting antivirals (DAAs) on chronic hepatitis C (CHC)-related hepatocellular carcinoma (HCC) remains controversial. We investigated the effect of eradicating CHC using DAAs on treatment outcomes in patients with CHC-related HCC treated with transarterial chemoembolization (TACE). Methods: This nationwide, multi-center, retrospective study recruited patients with CHC-related HCC treated with TACE as the first-line anti-cancer treatment, and who achieved a sustained virological response (SVR) using DAAs (DAA group) between 2006 and 2017. Patients achieving an SVR following interferon-based treatment (IFN group) and those without treatment (control group) were also recruited for comparison. Results: A total of 425 patients were eligible for the study. Of these, 356 (83.8%), 26 (6.1%), and 43 (10.1%) were allocated to the control, IFN, and DAA groups, respectively. A multivariate analysis showed that liver cirrhosis, segmental portal vein thrombosis, and larger maximal tumor size independently predicted an increased risk of progression (all p < 0.05), whereas, the DAA group (vs. IFN and control groups) independently predicted a reduced risk of progression (hazard ratio (HR) = 0.630, 95% confidence interval 0.411–0.966, p = 0.034). The cumulative incidence rate of HCC progression in the DAA group was significantly lower than that in the IFN and control groups (p = 0.033, log-rank test). In addition, the DAA group (vs. IFN and control groups) was independently associated with a reduced risk of mortality (p = 0.042). Conclusions: DAA treatment provided significantly prolonged progression-free survival in patients with CHC-related HCC treated with TACE compared to that in patients administered IFN or no treatment. © 2020, Springer Science+Business Media, LLC, part of Springer Nature. | * |
dc.language | English | * |
dc.publisher | Springer | * |
dc.subject | Direct-acting antiviral | * |
dc.subject | Hepatitis C virus | * |
dc.subject | Hepatocellular carcinoma | * |
dc.subject | Progression | * |
dc.subject | Transarterial chemoembolization | * |
dc.title | Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study | * |
dc.type | Article | * |
dc.relation.issue | 7 | * |
dc.relation.volume | 66 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 2427 | * |
dc.relation.lastpage | 2438 | * |
dc.relation.journaltitle | Digestive Diseases and Sciences | * |
dc.identifier.doi | 10.1007/s10620-020-06533-7 | * |
dc.identifier.scopusid | 2-s2.0-85089894151 | * |
dc.author.google | Hyun H.K. | * |
dc.author.google | Cho E.J. | * |
dc.author.google | Park S.Y. | * |
dc.author.google | Hong Y.M. | * |
dc.author.google | Kim S.S. | * |
dc.author.google | Kim H.Y. | * |
dc.author.google | Heo N.-Y. | * |
dc.author.google | Park J.G. | * |
dc.author.google | Sinn D.H. | * |
dc.author.google | Kang W. | * |
dc.author.google | Jeong S.W. | * |
dc.author.google | Song M.J. | * |
dc.author.google | Park H. | * |
dc.author.google | Lee D. | * |
dc.author.google | Lee Y.S. | * |
dc.author.google | Cho S.B. | * |
dc.author.google | An C.S. | * |
dc.author.google | Rhee H.J. | * |
dc.author.google | Lee H.W. | * |
dc.author.google | Kim B.K. | * |
dc.author.google | Park J.Y. | * |
dc.author.google | Kim D.Y. | * |
dc.author.google | Ahn S.H. | * |
dc.author.google | Han K.-H. | * |
dc.author.google | Lee J.-H. | * |
dc.author.google | Yu S.J. | * |
dc.author.google | Kim Y.J. | * |
dc.author.google | Yoon J.-H. | * |
dc.author.google | Tak W.Y. | * |
dc.author.google | Kweon Y.O. | * |
dc.author.google | Yoon K.T. | * |
dc.author.google | Cho M. | * |
dc.author.google | Cheong J.Y. | * |
dc.author.google | Park S.H. | * |
dc.author.google | Kim S.U. | * |
dc.author.google | The Korean TACE Study Group | * |
dc.contributor.scopusid | 김휘영(56493773500) | * |
dc.date.modifydate | 20240429140130 | * |